DJ Khaled Opens Up About Losing 75 Pounds With Wegovy and His Decision to Seek Obesity Treatment

DJ Khaled says he has lost 75 pounds using Wegovy over the past year and is speaking publicly about the health concerns that prompted him to seek medical treatment for his weight. The 50-year-old rapper and music producer confirmed the weight loss on 12 November, as drugmaker Novo Nordisk announced a new partnership with him.
Khaled said the 75 pounds represented about 25% of his body weight. He began taking the prescription injection in late 2025 and plans to share details of his diet, exercise and treatment routine.
Performance Difficulties Prompted a Doctor's Visit
Khaled said an October 2025 concert marked a turning point. During the performance, he struggled to stand after kneeling onstage, as per a report by People. Friends subsequently contacted him because they had noticed his heavy breathing, prompting him to reconsider his health and overall wellbeing more seriously.
He had already been exercising and trying to improve his eating habits before seeking treatment. However, walking and playing golf had not produced the results he wanted, according to his account published by Novo Nordisk. After discussing his options with his doctor, he began using Wegovy alongside lifestyle changes.
Family, Golf and His Weight-Loss Routine
Khaled said his two sons and his responsibilities as a father influenced his decision. He now regularly walks an entire 18-hole golf course instead of using a buggy, covering several miles in a session. In an interview with E! News, he said he typically reaches more than 10,000 steps daily and often eats lunch after golf and dinner with his children.
He said that he now weighs roughly 210 to 212 pounds and would like to reach 200. Khaled said he weighed approximately 295 to 300 pounds when he began his health journey. He has since lost about 90 pounds overall, including 75 pounds during his treatment with Wegovy.
The musician said he wanted to explain his treatment after seeing public speculation about his appearance. His new campaign with Novo Nordisk will document his daily routine and encourage discussions with medical professionals.
He previously appeared in Novo Nordisk's 2026 Super Bowl advertisement promoting the Wegovy oral pill, although his own treatment involves injections.
Wegovy Treatment for Obesity and Excess Weight
Wegovy contains semaglutide, a medicine that acts on the GLP-1 hormone pathway to reduce appetite and food intake.
In the United States, its injection is authorised for long-term weight management in people with obesity and certain people who are overweight, alongside changes to diet and physical activity. It is also approved to reduce cardiovascular events in eligible adults with established heart disease.
In a 68-week trial involving 1,961 adults without diabetes, participants receiving weekly semaglutide injections lost an average of 14.9% of their starting weight. Those receiving a placebo lost 2.4% on average. Khaled's reported results are his individual experience and do not indicate what other patients will achieve.
Common side effects include nausea, vomiting, diarrhoea and constipation. Regulators also warn about potentially serious conditions, including pancreatitis and gallbladder disease. Wegovy carries a warning about thyroid tumours observed in rodents, although whether the medicine causes these tumours in humans remains unknown.